About T-Knife
T-Knife develops T cell receptor engineered T cell therapies for patients with solid tumors. The company designs T cell therapies using proprietary platforms and synthetic biology capabilities. T-Knife is a biopharmaceutical company.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
San Francisco, United States
Year Founded
2018
Team Size
11-50
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
t-knife.com
Domain Registered Date
Oct 27, 2015
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $110,000,000 · Series-B+
fundraisingfox.com
- Capital Raise
Raised $78,000,000 · Series-A
- Milestone
Company founded
San Francisco, United States
- Milestone
Website domain registered
t-knife.com
Investors & Backers
Andera Partners
Boehringer Ingelheim Venture Fund
CaaS Capital Management
Casdin Capital
EQT Life Sciences
Fidelity
Qatar Investment Authority
RA Capital Management
Sixty Degree Capital
Versant Ventures
Funding History
Series-B+
· Aug 2, 2021
$110,000,000 fundraisingfox.com
Series-A
· Aug 6, 2020
$78,000,000 Source
Founders & Leadership
Camille Landis
CBO / CFO
Work email & phone locked
Unlock →
Elisa Kieback
Founder
Work email & phone locked
Unlock →
Simone Silva Steiner
Chief Technical Operations Officer
Work email & phone locked
Unlock →
Thomas Blankenstein
Scientific Founder
Work email & phone locked
Unlock →
Tom Soloway
Chief Executive Officer
Work email & phone locked
Unlock →
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026